Skip to main content
. Author manuscript; available in PMC: 2021 Jul 12.
Published in final edited form as: Mol Cancer Ther. 2020 Nov 17;20(1):50–63. doi: 10.1158/1535-7163.MCT-20-0480

Figure 1. Schematic overview of study design.

Figure 1

In terms of serine/glycine metabolism, breast cancers (BRCA) can largely be divided into serine/glycine uptake or synthesis addicted. Using a yeast model system that upregulates serine/glycine synthesis, we selected repurposed compounds that target serine/glycine synthesis in the breast cancer context. After thorough in vitro validation, the most promising, and clinically used, repurposed compound was selected for the rational design of a novel combination therapy for serine/glycine synthesis addicted breast cancer. Human enzymes involved in serine/glycine synthesis are indicated in blue. PHGDH: phosphoglycerate dehydrogenase; PSAT1: phosphoserine aminotransferase; PSPH: phosphoserine phosphatase; SHMT1/2: cytosolic/mitochondrial serine hydroxymethyltransferase; TCA: tricarboxylic acid.